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Celiac disease (CD) is a permanent intolerance to gluten that results in damage to 
the mucosa of the small intestine. This damage consists of mucosal inflammation and 
loss of absorptive surface area and is manifested by a broad spectrum of symptoms 
and nutritional deficiencies. The immune mediated damage to small bowel mucosa 
triggered by an immune response to the gliadin fraction of gluten, a component of 
wheat, barely and oats. CD can present at any age after the introduction of 
gluten into the diet. During Infant and childhood CD can present with failure to thrive, 
vomiting, diarrhea, constipation, rickets, occipital seizures, and short stature. In 
adults, CD may present with iron-deficiency anemia, diarrhea, infertility, nausea, 
vomiting, abdominal pain, weight loss, and pathologic fractures. CD is associated 
with specific MHC class II alleles that map to the HLA-DQ locus, The HLA-DQ2, DQ8 
alleles associated with increased susceptibility to CD.  
Since there are no previous studies performed to evaluate the CD in our area, 
therefore this study was performed to determine the occurrence of CD among 
children suffering from chronic diarrhea in Gaza City, to investigate the role of 
ASMA in false negative EMAs results, to propose TTG as an alternative 
solution for masking problem and  To highlight the CD in Gaza Strip for the first 
time. 
The results of this study by using EMAs test showed an occurrence of CD (3.25%), 
but when they were analyzed by using (TTG IgG, IgA) the occurrence was (12.2%), 
Our results also showed that the occurrence of ASMA was (28.5%), which may mask 
the EMAs  antibodies and hence giving false negative results of EMAs, the four 
positive subjects for EMAs showed positive results when they were tested for(TTG 
IgG, IgA), these results mean that the two tests have the same sensitivity, and finally 
our finding showed that the total IgA deficiency represent (33.3%) from all (TTG IgG, 
IgA) positive subjects, these results showed false negative results for (TTG IgA), so 
the class IgG of EMAs and TTG must be done to CD patients with total IgA 
deficiency. 
It is recommended to follow the protocol in figure 6.1  for laboratory diagnosis of CD, 
to Introduce the genetic analysis of CD to identify persons with increased risk of 
having the disease, and to adopt HPE as a golden standard test for clinical 
assessment of the patients with CD and to confirm the disease diagnosis......... ......        
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Arabic Abstract  
  
  
المتكرر التشخيص المناعي لمرض حساسية القمح بين األطفال اللذين يعانون من اإلسهال 
  .في قطاع غزة
  
المبطن ينتج مرض حساسية القمح عن عدم تحمل األمعاء لمادة الجلوتين مما ينتج عنه أضرار جسيمة للغشاء 
لألمعاء الدقيقة وهذه األضرار تكون على شكل التهاب للغشاء المخاطي المبطن لألمعاء الدقيقة ونقص كبير في مساحة 
شخيص هذا المرض عن طريق األعراض الكثيرة والمختلفـة التـي تـصيب ويتم ت ، )الخمالت(وحدات االمتصاص 
رد الفعل المناعي ضد الغشاء المبطن لألمعاء الدقيقة يحدث نتيجـة ، المرضى نتيجة لسوء امتصاص الغذاء المهضوم 
  .رلجاودا وهي جزء من مادة الجلوتين الموجودة في القمح والشعير واGLIADIN)(للتفاعل المناعي لمادة الجاليدين 
ويظهر في األطفال الرضع بصورة ضعف ، مرض حساسية القمح يمكن أن يحدث في أي عمر  بعد أكل مادة الجلوتين 
ولكن األعراض في سن البلوغ تكون فقر دم بسبب ، تشنجات وقصر في القامة ، كساح، إمساك، إسهال، قيئ، في النمو 
أما األمهات الالتـي لـم ،  ونقص في الوزن وكسور بالعظام قيئ وألم في البطن ، غثيان، عقم، إسهال، نقص الحديد 
  .يعالجن من هذا المرض يكون الطفل المولود ناقص الوزن ويزداد احتمالية اإلجهاض لهذه النساء
وحيث انه ال يوجد دراسات سابقة أجريت لتقييم هذا المرض في منطقتنا فقد قمت بإجراء هذه الدراسة بهـدف تحديـد 
للتحقق مـن مـدى وأيضا ، ون من حاالت اإلسهال المزمنة في مدينة غزةن بين األطفال الذين يعانسبة حدوث المرض 
لتشخيص ) TTG( إلدخال فحوصات مناعية جديدة مثل  السلبية،EMAs على نتائج الASMAتأثير األجسام المضادة 
  .المرض وأخيراً لتسليط الضوء على مرض حساسية القمح للمرة األولى في قطاع غزة
 ولكن باستخدام فحص EMAsباستخدام فحص الـ % 3.25أظهرت الدراسة أن النسبة العامة لمرض حساسية القمح 
(TTG IgG,IgA) وكانت جميع الحاالت االيجابية لفحص الـ ، %12.2 ارتفعت النسبة إلىEMAs ًايجابية أيـضا 
  .وهذا يعني أن الفحصين لهما نفس الحساسية، TTG IgG IgAلفحص 
 ) ,TTG IgG( من جميع الحاالت االيجابية لفحص %33.3 كانت Total IgAالدراسة أيضاً أن نسبة نقص وأظهرت 
IgA وهذه الحاالت أظهرت نتيجة سلبية لفحص TTG IgA لذلك يجب عمل فحص IgG للـــ EMAs و الـــ 
TTG لمرضى حساسية القمح اللذين لديهم نقص في Total IgA.  
 VI
للتشخيص المناعي لمرض حساسية ) 6.1(سة فإننا نوصي بإتباع اآللية المقترحة في الشكل وبناء على نتائج هذه الدرا 
وأيضاً نوصي بعمل التحاليل الجينية الخاصة بهذا المرض لمعرفة وتشخيص األفراد الذين لديهم عوامل الخطر ، القمح
 . لمرض حساسية القمحوأخيراً ليكون الفحص النسيجي هو الخيار األقوى لتأكيد التشخيص، لإلصابة به
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Celiac Disease (CD) is a permanent intolerance to gluten that results in 
damage to the mucosa of the small intestine. This damage consists of 
mucosal inflammation and loss of absorptive surface area and is manifested 
by a broad spectrum of symptoms and nutritional deficiencies (1). 
The mucosal damage is primarily cellular, untreated celiac disease is also 
associated with a humoral immune response directed against the reticulin and 
endomysium of connective tissue, “endomysial antibodies” (EMAs), and 
against various peptides derived predominantly from wheat, “antigliadin 
antibodies” (AGAs). EMAs have been proposed as the most reliable serologic 
marker for celiac disease (2). 
Antibodies to the enzyme tissue transglutaminase (TTG) are found in an 
overwhelming majority of cases, and cross-react with gluten. Tissue 
transglutaminase modifies gluten peptides into a form that may stimulate the 
immune system more effectively. The use of Tissue Transglutaminase 
Antibody (TTG) screening may soon replace the use of the small-bowel 
biopsy to diagnose celiac disease in children (3). 
Celiac disease shows incomplete penetrance, as the gene alleles associated 
with the disease appear in most patients, but are neither present in all cases 
nor sufficient by themselves to cause the disease. Over 95% of Celiac  
patients have an isoform of DQ2, major histocompatibility antigens 
(MHC,class  antigens) and DQ8 ,which are inherited in families. The reason  װ
these alleles produce an increased risk of celiac disease is that the receptors 
formed by these genes bind to gliadin peptides more tightly than other forms 
of the antigen-presenting receptor. Therefore, these forms of the receptor are 
more likely to activate T lymphocytes and initiate the autoimmune process (4). 
The inflammatory process, mediated by T cells, leads to disruption of the 
structure and function of the small bowel's mucous lining, and causes 
malabsorption as it impairs the body's ability to absorb nutrients, minerals and 
fat-soluble vitamins (A, D, E and K) from food. Lactose intolerance may be 
present due to the decreased bowel surface and reduced production of 
lactase, but typically resolves once the condition is treated. 
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Alternative causes of this tissue damage have been proposed and involve 
release of interleukin 15 and activation of the innate immune system by a 
shorter gluten peptide. This would trigger killing of enterocytes by 
lymphocytes in the epithelium. The villous atrophy seen on biopsy may also 
be due to unrelated causes, such as tropical sprue, giardiasis and radiation 
enteritis. While positive serology and typical biopsy are highly suggestive of 
Celiac  disease, lack of response to diet may require these alternative 
diagnoses to be considered ( 5). 
Celiac disease affects people differently. Symptoms may occur in the 
digestive system like, chronic diarrhea, abdominal blotting and pain, or in 
other parts of the body like anemia, bone or joint pain, osteoporosis, muscle 
cramps, seizures, infertility, sores inside mouth, failure to thrive, itchy skin 
rash called dermatitis herpetiformis. 
The prevalence of clinically diagnosed disease (symptoms prompting 
diagnostic testing) is 0.05–0.27% in various studies. People of African, 
Japanese and Chinese descent are rarely diagnosed; this reflects a much 
lower prevalence of the genetic risk factors. Population studies also indicate 
that a large proportion of Celiac patients is undiagnosed; this is due to many 
clinicians being unfamiliar with the condition (6). 
A large multicentre study in the U.S. found a prevalence of 0.75% in not-at-
risk groups, rising to 1.8% in symptomatic patients, 2.6% in second-degree 
relatives of a patient with Celiac  disease and 4.5% in first-degree relatives. 
This profile is similar to the prevalence in Europe (7). 
Treatment for celiac disease is a strict gluten-free diet. This includes 
elimination of the storage proteins (prolamines) of wheat, barley, rye and oats. 
It also includes eliminating gluten in over-the-counter medications by carefully 
checking the labels for ingredients such as hydrolyzed plant and vegetable 
proteins, modified food starch, cereal solids, and the more obvious oat hull 
fibers, wheat flour and glutens. Home food preparation requires a strong 
commitment to exclude glutens (8). 
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1.2. General Objectives 
1. To estimate the occurrence of the celiac disease (CD) among 
diarrheic children in Gaza strip. 
1.3. Specific objectives 
2. To investigate the role of anti smooth muscle antibodies (ASMA) 
in false negative EMAs results. 
3. To Propose TTG as an alternative solution for masking problem. 
1.3. Significance  
v There is a large fraction of diarrheic children who are  misdiagnosed 
and thus don’t  respond to treatment as the drugs are directed 
toward other disease. 
v CD is currently diagnosed by EMAs  in the Ministry of Health which 
is associated with high percentage of false negative results when 
compared to biopsy. 
v The evaluation of CD occurrence in Gaza strip for the first time will 
help the decision makers to apply the suitable diagnosis and 
management strategies of this disease. 














1.4. Research problem 
In Palestine the screening test of CD is based on one test which is (EMAs). 
EMAs is specific and sensitive test, its usage for diagnosis  of CD might be 
accompanied by high percentage of false negative results. This might result 
from the high frequency of a positive anti smooth muscle antibodies (ASMA) 
that might mask EMAs when present. Moreover IgA deficiency in children may 
result in false negative as well. According to my experience in the field, I 
noticed that there is a high frequency of (ASMA) which may mask EMAs and 
gives false negative results of CD. According to the researcher knowledge 
there is no information about this disease in our area, This study aims at 
bringing into focus the celiac disease in Gaza Strip and propose a standard 
protocol to be implemented to achieve an accurate and dependable laboratory 
results.  
 




























































2.1 Background  
 
Celiac disease (CD) is a gluten enteropathy occurring in both children and                      
adults. CD also referred to as celiac sprue, gluten-sensitive                                           
enteropathy, non-tropical sprue, in addition to a host of other names. The 
condition is characterized by a sensitivity to gluten that results in inflammation 
and atrophy of the mucosa of the small intestine. Clinical manifestations 
include malabsorption with symptoms of diarrhea, steatorrhea, and nutritional 
and vitamin deficiencies. Secondary immunologic illnesses, such as atopic 
dermatitis, dermatitis herpetiformis, alopecia and aphthous ulcers, may be the 
primary presentation (9). 
Normally, ingested food does not elicit a local or systemic immune response. 
Ingestion of protein down-regulates the intestinal immune response to that 
protein. This phenomenon is known as oral tolerance. In patients with celiac 
disease, the immune system is abnormally activated by gluten, specifically the 
gliadin portion of wheat protein, and prolamines (insoluble proteins) in rye, 
barley and oats. It is thought to result from the activation of both a cell-
mediated (T-cell) and humoral (B-cell) immune response upon exposure to 
the glutens (prolamins and glutenins) of wheat, barley, rye, and oats, in a 
genetically susceptible person. Thus, celiac disease is a genetic, 
immunologically mediated, small intestine enteropathy in which mucosal villi 
are destroyed by cellular and humoral-mediated immunologic reactions to 
gliadin protein. The loss of functioning villi limits the ability of the small 
intestine to absorb nutrients, thus adversely affecting all systems of the body 
.The immunologic response to gluten may also occur secondarily in other 
bodily tissues, an example being dermatitis herpetiformis (8). 
2.2 History 
Celiac disease may have an ancient history dating back to the 1st and 2nd 
centuries AD. The first clear description was given by Samuel Gee in 1888. 
He suggested that dietary treatment might be of benefit. The doctoral thesis of 
Wim Dicke of 1950 established that exclusion of wheat, rye and oats from the 
diet led to dramatic improvement. Dicke's colleagues, Weijers and Van de 
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Kamer, showed that measurement of stool fat reflected the clinical condition. 
Histological abnormalities of the lining of the small intestine were 
demonstrated beyond doubt by Paulley in 1954 and techniques of per-oral 
biopsy described by Royer in 1955 and Shiner in 1956 afforded reliable 
diagnosis. A relationship with dermatitis herpetiformis was suggested by 
Samman in 1955 and established by Shuster and Marks in 1965 and 1968. 
The Celiac Society (now Celiac UK) was founded in 1968 and similar 
societies now exist across the world. They provide an extremely valuable 
service. Present problems include definition of the tolerated levels of gluten, 
whether oats are toxic for some or all celiacs and the likelihood that the 
condition is relatively common and frequently without classical symptoms. 
Hope for the future is that more convenient methods of treatment will follow 
better understanding (10). 
In 1996, research indicated a significant reduction in malignancies when 
celiac disease was treated with a gluten-free diet. Researchers continue to 
investigate celiac disease, honing in on the exact causes and implications for 
treatment (11). 
2.3 Epidemiology 
The researchers conducted studies about the prevalence of celiac disease, 
they concluded that the true prevalence of CD is difficult to estimate because 
of the variable presentation of the disease, particularly since many patients 
can have little or no symptoms. With this limitation in mind, the prevalence of 
the disease is highest in Celtic populations where estimates of 1:300 to 1:122 
have been described. The prevalence of CD in North America has been 
estimated to be 1:3000, while the prevalence in at-risk groups such as first-
degree relatives of CD patients was 1:22. CD can affect persons of many 
ethnic backgrounds, but appears to rarely affect persons of purely Chinese, 
Japanese, or Afro-Caribbean decent (12). 
The prevalence of clinically diagnosed disease (symptoms prompting 
diagnostic testing) it was found to be 0.05–0.27% in various studies. However, 
population studies from parts of Europe, South America, Australia and the 
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USA (using serology and biopsy) indicate that the prevalence may be 
between 0.33 and 1.06% in children  and 0.18–1.2% in adults (13). People of 
African, Japanese and Chinese descent are rarely diagnosed; this reflects a 
much lower prevalence of the genetic risk factors. Population studies also 
indicate that a large proportion of celiac patients are undiagnosed; this is due 
to many clinicians being unfamiliar with the condition (14). 
A large multicentre study in the U.S. found a prevalence of 0.75% in not-at-
risk groups, rising to 1.8% in symptomatic patients, 2.6% in second-degree 
relatives of a patient with celiac disease and 4.5% in first-degree relatives. 
This profile is similar to the prevalence in Europe (15). 
In Collin study the incidence of CD in adults varied from low of 1.27 in 
Denmark and 3.08 in England to high of 17.2 cases per 100,000 in Finland, 
the incidence of CD in child age 0-5 year varied from 2.15 to 51 cases per 
100,000 (16). 
The incidence was found to be one case in every 1,000 live birth ,with a range 
from one in 250 to 4000.In United state the prevalence was found to be one in 
250 (17). 
2.4 Pathogenesis 
The pathogenesis of CD is as yet not fully elucidated. Susceptibility to CD, 
and its activation and perpetuation, involve a combination of environmental 
and genetic factors, and immunological mechanisms. (18). 
Normally, ingested food does not elicit a local or systemic immune response. 
Ingestion of protein down-regulates the intestinal immune response to that 





2.4.1 The role of dietary proteins in disease pathogenesis. 
CD is activated by proteins in the dietary cereal grains wheat, rye, and barley. 
Although the disease-activating proteins in these grains are widely termed 
“gluten” (18). 
The term "gluten" is, in a sense, a generic term for the storage proteins that 
are found in grains. In reality, each type of protein, gliadin in wheat, secalin in 
rye, hordein in barley, avenin in oats, zein in corn and oryzenin in rice - is 
slightly different from the others. The "gluten" in wheat, rye, barley, and in a 
much lower amount, oats, contains particular amino acid sequences that are 
harmful to persons with celiac disease. The damaging proteins are particularly 
rich in proline and glutamine (especially the amino acid sequences which are 
in the following orders: Pro-Ser-Gln-Gln and Gln-Gln-Gln-Pro). As peptides, 
some cannot be broken down any further. In people with celiac disease, this 
stimulates T-cells to produce antibodies. The antibodies, in turn, attack the villi 
in the small intestine, reducing their ability to absorb nutrients. It is important 





Zizaneae Oryzeae Hordeae Aveneae Festuceaea Chlorideae




The Grass Family - (GRAMINEAE)
 
   
(Figure 2.1)  Taxonomy of some dietary grains (21) 
Triticeae Tribe  
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Wheat, barley, and rye, which contain the CD-activating proteins gluten, 
hordein, and secalin, respectively, are derived from the Triticeae tribe of the 
grass (Gramineae) family. In contrast, oats, which contain few CD-activating 
proteins, are more distantly related, as are rice, maize, sorghum, millet, Job’s 
tears, and teff.( 21) 
2.4.2 The role of Genetic factors: MHC class II HLA-DQ alleles. 
in disease pathogenesis. 
In a study reported about the genetic etiology of celiac disease, he concluded 
that  the pathogenesis of CD is firmly rooted in host genetic factors. This was 
first evident from clinical observations of multiple cases of CD within families, 
and the high (approximately 70%–75%) rate of concordance for CD among 
monozygotic twins (22). It is known that CD is associated with specific MHC 
class II alleles that map to the human leukocyte antigen (HLA-DQ) locus. 
Moreover, the presence of specific HLA-DQ alleles is necessary, although not 
sufficient, for the phenotypic expression of CD in virtually all affected 
individuals, irrespective of geographic location (21). The vast majority of celiac 
patients have one of two types of HLA DQ, a gene that is part of the MHC 
class II antigen-presenting receptor (also called the human leukocyte antigen) 
system and distinguishes cells between self and non-self for the purposes of 
the immune system. There are 7 HLA DQ variants (DQ2 and D4-9). Two of 
these variants—DQ2 and DQ8—are associated with Celiac disease. Every 
person inherits two copies, one from each parent. The gene is located on the 
short arm of the sixth chromosome, and as a result of the linkage this locus 
has been labeled CELIAC1  (23). This HLA-DQ2 is present in at least 90%–
95% of patients with CD, although a very small number of CD patients have 
been reported in whom only 1 of these DQ2 alleles is present (that is, HLA-
DQB1*0202 or, rarely, HLA-DQA1*05) The HLA-DQ8 heterodimer found in 
the remaining 5%–10% of patients with CD is formed by the β chain and α 
chain encoded by HLA-DQB1*0302 and HLA-DQA1*03, respectively (21).  
The association of HLA and pathogenesis was studied and found that the 
HLA-DQ2 and HLA-DQ8 heterodimers on antigen presenting cells (APCs) can 
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bind and subsequently present “gluten” peptides to populations of 
lymphocytes (CD4+ T cells) in the lamina propria of the small intestine (24). 
 Because the peptide-binding groove of HLA-DQ2 and HLA-DQ8 favors the 
binding of peptides with negatively charged residues at key anchor positions. 
Such negatively charged amino acids are largely absent from native “gluten” 
peptides generated in the human intestinal tract. However, this puzzle was 
solved after the discovery that the target antigen of an autoantibody present in 
many patients with CD was a calcium-dependent tissue transglutaminase 
(TTG) (25). Tissue TTG, which is released in the intestinal mucosa during 
tissue injury, has a role in tissue repair and cross-links proteins by forming 
isopeptide bonds between glutamine and lysine residues. However, tissue 
TTG also has a high avidity for “gluten” peptides and, under certain conditions 
(for example, low pH) and in the absence of lysine residues, can deamidate 
glutamine, which converts neutral glutamine to negatively charged glutamic 
acid. Further studies indicated that tissue TTG, has specificity for only 
selected glutamine residues in the glutamine and proline-rich “gluten” 
peptides, which depends on the amino acids neighboring the target glutamine 
residue. Some, but not all, of the deamidated “gluten” peptides, by virtue of 
having negatively charged glutamic acid residues, manifest an increased 
binding affinity for the disease-relevant HLA-DQ2 or HLA-DQ8 molecules(26). 
Once bound to HLA-DQ2 and HLA-DQ8, the “gluten”-peptide–HLA-DQ 
complexes can activate T cells in the mucosa of the small intestine that 
recognize these complexes. The production of IFN-γ is a signature of “gluten” 
peptide–specific HLA-DQ2– and HLA-DQ8–restricted T cells that are isolated 
from the mucosa of the small intestine of CD patients, and it is considered to 
have a key role in the downstream initiation of mucosal damage (27). 
2.4.3 A model of CD immunopathogenesis 
Researchers have proposed a model to conceptualize the role of the adaptive 
T cell response in CD pathogenesis (Figure 2.2) divides pathogenesis into 3 
phases: luminal and early mucosal events; activation of pathogenic CD4+ T 
cells; and events leading to tissue damage. In the first phase, an individual 
ingests “gluten.” “Gluten” is digested to peptides, but because of the lack of 
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prolyl endopeptidases among the gastric, pancreatic, and brush border 
enzymes, residual, relatively large “gluten” peptides that are rich in proline 
and glutamine remain in after initial digestion. For 99% of individuals, 
including most of those who carry the CD susceptibility alleles that encode 
HLA-DQ2 and HLA-DQ8, this does not present a problem, at least in terms of 
developing CD. However, in those HLA-DQ2– or HLA-DQ8–positive 
individuals with increased susceptibility to CD, because of additional genetic 
and/or immunological factors and/or an adverse set of environmental events 
(for example, concurrent infection with an enteric virus), “gluten” peptides set 
in motion a series of immunological events that culminate in the 
immunopathology of CD (21).  
Partially digested “gluten” peptides gain access to antigen presenting cells 
(APCs) in the subepithelial region of the small intestine, and the pathway(s) 
involved here is not yet determined but might include paracellular passage 
through a damaged epithelial cell layer, transepithelial passage that can cross 
the epithelial cell layer . It is probable that the uptake of “gluten” peptides into 
a microenvironmental milieu in the small-intestinal mucosa suited for disease 
development is facilitated by a transient infection or other cause of 
inflammation in the small intestine. Viral infections would seem to be prime 
culprits to set the stage for a mucosal T cell response to “gluten” peptides. 
Having set the conditions for developing a T helper (Th1) cell response, in the 
second phase, “gluten” peptides bound to  HLA-DQ2 or HLA-DQ8 encounter 
“gluten”-specific T cells that become committed to Th1 cytokine production. In 
the third phase, the release of interferon γ (IFN-γ) and other cytokines, which 
perpetuate the ongoing response and alter key mucosal functions including 
intestinal permeability, can also result in the activation and release of 
enzymes that can damage the mucosa. This results in a loss of villous 
structure and crypt hypertrophy ( 21). 
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At endoscopy, the appearance of the duodenal mucosa will vary depending 
on the severity of the CD. Latent CD typically demonstrates no gross 
abnormality and demonstrates normal semicircular folds. With overt disease, 
the folds may show a scalloped, or notched, appearance; in severe disease, 
the folds may be decreased in size and number or be completely absent (28). 
As the clinical and endoscopic spectrum of CD has broadened, the range of 
histologic findings compatible with the diagnosis of serologically positive CD 
has also increased: 
• Increased intraepithelial lymphocytes (IEL; Fig. 2.3). This is the first 
and most sensitive marker of the effects of gluten on the small-bowel 
mucosa; thus, it is the major histological feature of CD. An increase is 
defined as >40 lymphocytes per 100 surface or upper-crypt 
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enterocytes. The vast majority are CD2+, CD3+; 70 to 90% are CD8+ 
T-cells. In latent forms of CD, an increase in IELs is often the only 
abnormality; villous architecture and lamina propria cellularity are within 
the normal range (29). 
• Increased cellularity in the lamina propria. In CD with villous/crypt 
abnormalities, plasma cells, lymphocytes, and eosinophils are 
increased in number, particularly in the upper half of the mucosa. The 
number of eosinophils may be striking; however, their increase is 
paralleled by the increase in mononuclear inflammatory cells, a finding 
that is against a diagnosis of allergic enteritis. Neutrophils are also part 
of the inflammatory response and may be numerous in the lamina 
propria (30) 
• Enterocyte damage (Fig. 2.4 A). In latent or minimal-deviation CD, the 
enterocytes are unremarkable. With severe injury, however, the apical 
cytoplasm is typically vacuolated; the cells themselves are shorter than 
normal and easily dislodged from the underlying basement membrane  
(31) 
• Villous atrophy/crypt hyperplasia (Fig. 2.4 B). These changes represent 
severe damage and can only be assessed in well-oriented sections . 
As a rule, villous-crypt ratios can be assessed if four or more crypts in 
parallel, nontangential array adjacent to one another can be identified 
in the biopsy specimen. Taking deeper sections through the tissue 
block may uncover such areas. Also, it should be recalled that villi 
overlying and adjacent to lymphoid nodules/follicles are normally 







2.5.1 Marsh stages 
• Marsh stage 0: normal mucosa 
• Marsh stage 1: increased number of intra-epithelial lymphocytes, 
usually exceeding 20 per 100 enterocytes. 
• Marsh stage 2: proliferation of the crypts of Lieberkuhn. 
• Marsh stage 3: partial or complete villous atrophy  
• Marsh stage 4: hypoplasia of the small bowel architecture (33) 
 
 
(Fig 2.3) Marsh Type I lesion. The villous is unremarkable except for a modest 





(Fig 2.4) Marsh Type III lesion. A, at low power, there is virtually complete villous 
blunting associated with crypt hyperplasia. B, at higher power, the increased number 
of surface intraepithelial lymphocytes and the damage to enterocytes are evident 
(33). 
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2.6 Clinical Presentation 
           Infancy  
During the first year of life, an infant may manifest celiac disease with 
intermittent vomiting, diarrhea, growth delay and failure to thrive. The 
incidence of this early classic presentation in infants has decreased. However, 
to prevent significant growth problems in infants, confirmation of celiac 
disease is important (34). 
Childhood  
Children with celiac disease may present with failure to thrive, vomiting, 
anorexia, short stature, anemia, hepatitis, epilepsy and other 
extragastrointestinal conditions. With age, these presentations become more 
subtle. The most frequent of their symptoms were abdominal pain, aphthous 
stomatitis and atopic dermatitis. Angular cheilitis and recurrent aphthous 
ulcers are frequent in children and adults with celiac disease (Figure 2.5 & 
2.6). These clinical findings should prompt the physician to consider the 
diagnosis of celiac disease (35). 
 









(Figure 2.6). Angular cheilitis in a patient with celiac disease (35).  
  
Young adults 
The initial presentation of celiac disease in patients in their 20s and 30s may 
be dermatitis herpetiformis (figure 2.7). This condition usually appears as 
clear or blood-tinged vesicles symmetrically distributed over the extensor 
areas of the elbows, knees, buttocks, shoulders and scalp. Intense pruritus 
and/or burning sensations in the area occur hours before the onset of the 
vesicle. Dermatitis herpetiformis flares after consumption of foods containing 
high amount of gluten. 
Small intestine biopsies from patients with dermatitis herpetiformis reveal 
features identical to those found in patients with celiac disease. In a study of 
the occurrence of malignancies and the survival of 305 patients with 
dermatitis herpetiformis from 1970 to 1992. It was indicated that the incidence 
of non-Hodgkin's lymphoma is significantly increased in patients with 
dermatitis herpetiformis. The results also confirmed no increase in mortality in 





(Fig 2.7) Dermatitis herpetiformis. Symmetric vesiculation, crusts and erosions are distributed 
over the extensor areas of the elbows, knees, buttocks, shoulders and scalp, with a tendency 
to grouping of individual lesions (36).......................................................................................... 
                                                                                                  
Adults  
Malabsorption. The varied signs and symptoms of malabsorption may be 
caused by celiac disease or many other diseases. Mild malabsorption may be 
asymptomatic. With its gradual onset, the classic manifestations of flatulence 
and bulky, greasy and foul-smelling stools may not be recognized by the 
patient as signs of celiac disease. Malabsorption should be suspected in any 
patient with weight loss and diarrhea, and the signs and symptoms of specific 
vitamin or nutritional deficiencies. The latter include visual disturbances, 
neuropathy, anemia, osteopenic bone disease, tetany, hemorrhagic diathesis 
or infertility (37).  
Anemia. Anemia is a frequent presentation of celiac disease. In one study, 
200 consecutive patients presenting to a hematology clinic were screened for 
antigliadin and antiendomysial antibodies. Patients with both positive titers 
underwent intestinal biopsy, and in 10 (5 percent), results were positive for 
celiac disease. The prevalence increased to 8.5 percent if the patients with 
macrocytic anemia and the patients with bleeding who responded to iron 
therapy were excluded. The authors of this study recommend including celiac 
screening in the diagnostic algorithm of patients with anemia( 38). 
Osteopenia. Osteopenia may be the initial finding in patients with celiac 
disease.  
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Seizures. There have been numerous reports of children and adults with 
seizures associated with celiac disease. Studies have provided some insight 
into this condition (39). 
2.6.1 Celiac disease iceberg 
The celiac iceberg is the model used to illustrate that Celiac  disease varies 
with respect to clinical presentation and severity of symptoms.(figure 2.8) 
Clinical Celiac  disease at the top of the iceberg depicts the relatively small 
proportion of the celiac population with typical symptoms, e.g. weight loss, 
failure to thrive and diarrhea.………………………………………………………..             
 
Silent Celiac  disease incorporates those people who have celiac disease 
yet display no typical overt symptoms. Diagnosis usually occurs as a result of 
screening, e.g. family history or type 1 diabetes. Some in this category have 
mild degrees of anemia or osteopenia. Those with clinical and silent disease 
have a typical celiac small bowel lesion.…………………………………………. 
 
Latent celiac disease describes people who may at times have a normal 
mucosa on a normal diet, yet at other times show villous atrophy which is 
responsive to gluten withdrawal.………………………………………………….. 
Healthy Individuals at the base of the iceberg are those who include gluten 
as part of their diet and have normal small bowel morphology even though 




       
(Figure 2.8) The celiac disease iceberg and spectrum of gluten sensitivity  (40). 
2.7 Differential diagnosis  
  
The combination of clinical, serologic, and histologic findings plus response to 
a gluten-free diet confirms the diagnosis of CD in most patients. 
The following tests anti-gliadin, anti-reticulin, IgA anti-human tissue 
transglutimase (TTG), and IgA anti-endomysial antibodies (EMAs) are 
medically necessary for any of the following indications: 
1. As a preliminary diagnostic test for persons with symptoms 
suggestive of celiac disease; or 
2. To monitor response to a gluten-free diet; or 
3. For screening first-degree relatives of individuals with celiac 
disease; or 
4. To screen persons with type 1 diabetes for celiac disease ( 41). 
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According to national institute of health ( NIH) Consensus Panel Statement 
on celiac disease, serological testing is the first step in pursuing a diagnosis of 
celiac disease.  The Consensus Statement recommends that the best 
available tests are the IgA anti-human tissue transglutaminase (TTG) and 
anti-endomysial IgA antibodies (EMAs) (42). 
 The blood tests can be divided into 2 different types of antibodies: those 
which are “anti-gluten”, and those that “anti-self”.  The “anti-gluten” antibodies 
are the anti-gliadin IgG and IgA.  The “anti-self” antibodies are anti-
endomysial IgA and anti-tissue transglutaminase IgA (43).  
2.7.1 Blood tests for CD 
A number of tests, sometimes collectively referred to as the Celiac Blood 
Panel, will aid the physician in diagnosis. The tests may include, but are 
not limited to:  
• Serologic Tests  
1. EMAs  (Immunoglobulin A anti-endomysial antibodies)  
2. AGA (IgA anti-gliadin antibodies)  
3. AGG (IgG anti-gliadin antibodies)  
4. TTGA (IgA anti-tissue transglutaminase) 
5. ARA (IgA anti-reticulin antibodies)   
• Tolerance or Measure of Digestion/Absorption Tests  
1. Lactose tolerance test.  
2. D-Xylose test (44) 
  
2.7.1.1 Immunoglobulin A anti-endomysium antibodies ( EMAs ) 
The endomysial connective tissue surrounding each muscle cell contains the 
smallest of the various types of blood vessels, the capillary as shown in Figure 2.9 
(45). 
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Circulating anti-endomysium autoantibodies (EMAs ) are directed against 
anamorphous supportive tissue surrounding smooth muscle cells and 
myofibroblasts of the gastrointestinal tract (46). 
This antibody was discovered in the early 1980’s, and rapidly gained use as part of 
a screening “celiac panel” by commercial labs in combination with antigliadin IgG 
and IgA.  Its major drawbacks are that it may be falsely negative in young children, 
in patients with IgA deficiency and a lesser degree of villous atrophy, and in the 
hands of an inexperienced laboratory (43). 
It was  reported that the serologic detection of anti-endomysium antibodies (EMAs) 
is used to support the diagnosis and to screen populations at risk (47) 
IgA-EMAs  are measured by indirect immunofluorescence, using tissue sections 
from either monkey esophagus or human umbilical cord  as shown in (Figure 2.10) 
(48). 
It was reported that the sensitivity of IgA-EMAs  ranges from 87% to 100%, and the 
specificity is between 91% and 100% (Table 2.1). Although IgA-EMAs  has proved 
to be a highly specific marker of CD, this type of autoantibodies are not always 
present in children younger than 2 years of age . The IgA EMAs  levels correlate 









(Table 2.1). Sensitivity and specificity of anti-gliadin IgG, anti-gliadin IgA, anti-endomysial 
IgA, and anti-tissue transglutaminase IgA for the diagnosis of celiac disease (50). 
Marker  Sensitivity Specificity 
Anti-gliadin IgG 57%-85% 47%-75% 
Anti-gliadin IgA 52%-90% 71%-90% 
Anti-endomysial IgA 86%-100% 90%-100% 
Anti-tissue transglutaminase IgA* 85%-100% 91%-100% 
The anti-endomysium antibody test is based on an immunofluorescent technique 
and, therefore, is time-consuming to perform, generally more expensive compared 
with other tests, and, because the interpretation is operator-dependent, potentially 
more prone to errors. However, its high specificity makes this test one of the most 




(Fig 2.9) The endomysial connective tissue surrounding each muscle cell contains 







 (Fig 2.10) IgA-EMAs  are measured by indirect immunofluorescence, using tissue 
sections from either monkey esophagus or human umbilical cord (48).  
  
  
The effect of immunoglobulin IgA deficiency in patients with CD on serological 
tests that used in the evaluation of CD patient was assessed. The result of the 
study revealed that the IgA deficient patients with CD yeild false negative 
serological results when we looking for the (IgA) of (EMAs ,TTG,AGA,). So 
the study recommended to use the IgG for serological tests (52). 
Another study recommended that the total serum IgA level is checked in 
parallel  as CD patients with IgA deficiency may be unable to produce the 
antibodies on which these tests  depend on. This may give false negative 
results. In those patients, IgG antibodies against TTG and EMAs  may be 
diagnostic (53). 
Anti-smooth muscle antibodies might mask the presence of anti-endomysial 
antibodies so the result of EMAs  will be false negative, so they  show that the 
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EMAs  response can be effectively unmasked by increasingly diluting anti-
smooth muscle antibodies-positive serum ( 54). 
2.7.1.2 Anti-gliadin antibodies 
Anti-gliadin antibodies are produced in response to gliadin which is a prolamin 
found in the wheat. The AGA IgG and IgA recognize a small piece of the 
gluten protein called gliadin. These antibodies became available during the 
late 1970s and were the first step towards recognizing CD as an autoimmune 
disorder. IgA and IgG antibodies directed against gliadin (AGA) are often 
elevated in untreated CD patients. However, AGA is not disease specific, and 
some patients with active CD lack these antibodies. In contrast, patients with 
diseases other than CD and healthy individuals occasionally have elevated 
levels of IgA-AGA and IgG-AGA (55). The sensitivity of IgA-AGA has been 
reported to vary from 52% to 100% and the specificity ranges between 71% 
and 100%. The sensitivity of IgG-AGA is similar to that of IgA-AGA, whereas 
the specificity of IgG-AGA can be as low as 50%. These antibodies disappear 
rapidly during a gluten-free diet (56). 
The IgG form of this test is most useful in children less than 2 years of age 
and in guiding diagnosis in individuals with IgA deficiency.  It is also used to 
monitor dietary compliance. In gluten-sensitive individuals, AGA testing is a 
routinely used blood test for possible presence of celiac disease, allergies or 
idiopathic phenomena. The measurement of AGA is done with Enzyme linked 
immunosorbent assay (ELISA) or radioimmunoassay (57). The importance of 
an ELISA test is that it is rapid, inexpensive, and run by a machine.  Thus the 
results are independent of observer variability.   (58) 
Antigliadin antibody (AGA) positivity disappeared in over 50% of cases, and is 
therefore a poor marker for celiac disease. The researchers did follow up AGA 
testing on 69 adults and 47 children who participated in a much larger study 
conducted four years ago and found that only 26 of the adults and 21 of the 
children still had detectable levels of AGA in their blood samples, and none of 
them were positive for IgA-class anti-endomysial antibodies. The researchers 
concluded that the appearance of AGA should be interpreted as a non-
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specific “immunomodulation phenomenon” that has low specificity as a 
diagnostic marker for celiac disease (59). 
 
In a study was performed to compare the usefulness of IgG and IgA 
antigliadin antibodies, IgA-endomysial antibodies, and intestinal permeability 
in diagnosing celiac disease in 102 adult patients with nonspecific abdominal 
symptoms. In addition, all patients underwent small bowel biopsy as a gold 
standard for the diagnosis of celiac disease. The results showed that Forty-
nine patients were ultimately diagnosed as having celiac disease because of 
flat mucosa. IgA-endomysial antibodies showed a sensitivity of 100%, but only 
55% specificity. IgG and IgA-antigliadin antibodies' sensitivity (73% and 82%, 
respectively) and specificity (74% and 83%, respectively) were much lower 
than EMAs (60). 
 
2.7.1.3 Tissue transglutaminase antibodies (TTG) 
 
Tissue transglutaminase  is an enzyme present in most organs. In the 
gastrointestinal tract, the enzyme is found intracellularly in enterocytes and 
myofibroblasts. Extracellularly, TTG is located in the membranes of entrocytes 
and in the subepithelial connective tissue of the small intestine. It has been 
demonstrated that TTG activity is increased in the mucosal lesions of patients 
with active CD (61).  
TTG can form cross-links between glutamine containing (acceptor) and lysine 
containing (donor) substrates by a transamidation reaction, which is strictly 
Ca2+-dependent. In the absence of donor substrates, or at low pH, 
transglutaminase-bound acceptor molecules may become deamidated. In 
addition to the transamidation activity, TTG may function as an intracellular 
GTPase. The two enzymatic functions are mutually exclusive (62,63). 
Intracellularly, in the GTP-bound form, TTG adapts a closed conformation that 
keeps the transamidation site inaccessible. Extracellularly, in the presence of 
Ca2+, TTG adapts an open conformation, which discloses the active site (64).  
TTG has a strong affinity for fibronectin, and it has been demonstrated that 
2:1 complexes between TTG and fibronectin are formed upon cellular release 
of  TTG (65). The biological function of TTG has not been clarified. However, 
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it has been suggested that TTG is involved in apoptosis, wound healing, and 
cell adhesion (66). Although TTG knock out mice are born healthy, lack of 
TTG in these animals cause an abnormal immune response due to the 
impaired capacity of macrophages to engulf apoptotic cells (67). Gliadins that 
contain a high percentage of glutamine are favoured acceptor substrates and 
TTG molecules may participate in the transamidation reaction either as 
acceptor or donor substrates (68). It has been revealed that TTG-gliadin 
complexes are formed in vitro as well as in the small intestine of CD patients. 
Moreover, immunostimulatory peptides of gliadin can be deamidated by TTG, 
which increases their binding to HLA-DQ2 and DQ8 molecules (69). 
Since TTG had been first described as the autoantigen of celiac disease in 
1997, it has been utilized to develop innovative diagnostic tools, However, it 
represents an improvement over the antiendomysial antibody assay because 
it is inexpensive, rapid and easy to performed. (58). 
 
The autoantigen of the EMAs  has been identified as TTG (70). The amino 
acid sequence of TTG is generally highly conserved among species, 
displaying an 80% homology between guinea pig and human TTG (71). Thus, 
the first generation of anti-TTG assays were based on TTG from guinea pig 
liver preparations (68). However, these antigens contained several 
contaminating proteins that decreased the specificity of these assays. 
Subsequently, when purified native and recombinant human TTG became 
available, it was demonstrated that human TTG bound IgA-TTG more potently 
than the guinea pig counterpart (72). ELISA using recombinant human TTG 
for detection of IgA-TTG were demonstrated to have sensitivities and 
specificities higher than 90% (73). The IgA-TTG levels decrease on a gluten-
free diet and reappear after the reintroduction of gluten into the diet (74). 
 
In a study reported by Vitoria and here colleagues to assess the sensitivity, 
specificity, and predictive value of TTG antibodies measured by a 
commercially available ELISA technique, compared with those of EMAs  and 
IgA antigliadin antibodies (AGA) for the diagnosis of celiac disease. Twenty-
seven serum samples were obtained from patients with untreated celiac 
disease, 37 from patients who had gluten withdrawn from their diets for 
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varying time spans, and 34 from control subjects without celiac disease. All 
were younger than 14 years. Presence of TTG antibodies and AGA was 
determined by ELISA and of EMAs  by indirect immunofluorescence. 
RESULTS: Twenty-six of 27 serum samples obtained from patients at the 
time of diagnosis of celiac disease were AGA positive. All 27 (concordance 
rate 100%) were positive for EMAs  and TTG antibodies. Of the 34 control 
subjects; 1 was for AGA and 2 for TTG-antibodies. All 34 were negative for 
EMAs . Sensitivity, specificity, positive predictive value, and negative 
predictive value within this group were, for TTG antibodies: 100%, 94%, 93%, 
and 100%, respectively; for EMAs : all four indexes were 100%; and for AGA: 
96%, 97%, 96%, 97%. Of 37 treated 2 AGA positive, 9 were EMAs  positive, 
and 6 were TTG antibodies positive. The concordance rate between EMAs  
and TTG antibodies was 100% in the group with untreated celiac disease, 
94% in the control subjects, and 76% in the group with treated celiac disease. 
It was concluded that Immunoglobulin A antibodies to tissue transglutaminase 
are new, highly sensitive, and specific markers of celiac disease. They can be 
determined easily by an accurate, comparatively cheap technique and thereby 
may advantageously replace the EMAs  marker traditionally used (75). 
According to the National institute of health (NIH)  Consensus Statement 
(2004), if an individual has suggestive symptoms and negative serological 
tests, it may be necessary to measure serum IgA to detect a selective IgA 
deficiency.  If an IgA deficiency is identified, an IgG-TTG or IgG-EMAs  test 
should be performed (42). 
The levels of IgG-TTG and IgA-TTG were positively correlated with the grade 
of mucosal villous atrophy and that the IgG-TTG levels corresponded with 
more severe manifestations of gluten enteropathy. Whereas elevated IgG-
TTG or IgA-TTG taken alone should be interpreted with caution, the combined 
assessment of high IgA-TTG and IgG-TTG levels predicted a severe villous 
atrophy. Hence, the biopsy procedure might not be needed to diagnose CD 
for patients with very high levels of both IgA and IgG against TTG. During a 
gluten-free diet, IgA-TTG mostly disappeared prior to clinical and mucosal 
recovery. Interestingly, the overall clinical condition in children was better 
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reflected by the IgG-TTG levels. For follow-up of adult IgA competent patients, 
assessment of IgG-TTG is also recommended, as their presence and levels 
might indicate a more severe disease (76). 
 
In another  study the researchers recommended using the anti-TTG as the 
initial test in both population screening and for individual cases suspected of 
having CD on the bases of symptoms or conditions associated with disease. 
The positive result should be tested for EMAs  as a second step in the 
screening process and if positive the patient should undergo an intestinal 
biopsy for conformation of the diagnosis (77). 
The clinical utility of a newly developed kit for antibodies IgG and IgA to 
human recombinant TTG in a large population  of CD patients was assessed. 
The results showed that the test is highly sensitive and specific for the 
detection of CD, and the results demonstrated that the test detects a 
substantial number of CD cases that were not recognized by IgA EMAs  (78). 
2.7.1.4 Anti reticulin antibodies 
IgA class reticulin antibodies react with connective tissue fibers and are most 
easily demonstrated on rat or mouse kidney substrates and also on rat or 
mouse stomach. IgA class reticulin antibodies are found in 60% of celiac 
disease patients. IgG class reticulin antibodies are occasionally found in other 
disease states, especially bullous dermatoses and in some normal subjects 
(79). Serum reticulin antibodies tests have been in use since 1971.The 
antigen has routinely been detected by a standard immunofluorescence 
method using unfixed cryostat sections of rat kidney, liver, and stomach as 
antigens. Positive results obtained by a typical staining pattern in both rat 
kidney and liver (80). 
 Two patterns that can be observed in the connective tissue fibers are referred 
to as reticulin 1 (R1) and reticulin 2 (R2). R1 is related to Celiac Disease, the 
staining pattern on a liver substrate exhibits nodular fluorescence around the 
portal tracts, up to the limiting plate of the hepatocyte, and a fine outline of the 
sinusoid. R1 sera in the kidney stains all around the tubules and the 
 29
Bowman's capsule. On smooth or striated muscle tissue there is a fluorescent 
"honeycomb" appearance. These antibodies are not species specific. 
R2 antibodies are species specific and only react with rat tissue.  R2 sera 
stains the thin sharp-edged fibers in the liver. In the stomach (longitudinal 
section), they appear as streaks between the gastric glands. These fibers are 
not found in great quantity in the muscularis mucosae but rather they are 
concentrated around the vessels in all organs. In the kidney, there is no 
staining of the "Bowman's Capsule" or between the tubules. Only the 
perivascular connective tissue stains in the liver and stomach. The staining 
can be mistaken for smooth muscle; care should be taken to evaluate closely. 
The R2 fibers are very thin and much sharper than smooth muscle fibers (81) 
 
2.7.1.5 D-Xylose test 
The D-xylose absorption test measures the level of D-xylose, a type of sugar, 
in a blood or urine sample. This test is done to help diagnose problems that 
prevent the small intestine from absorbing nutrients in food. 
D-xylose is normally easily absorbed by the intestines. When problems with 
absorption occur, D-xylose is not absorbed by the intestines, and its level in 
blood and urine is low. 
A test for D-xylose is done to determine if malabsorption syndrome is causing 
symptoms, such as chronic diarrhea, weight loss, and weakness. A person 
with malabsorption syndrome is unable to absorb nutrients, vitamins, and 
minerals from the intestinal tract into the bloodstream. It is also used to find 
the cause of a child's failure to gain weight, especially when the child seems 
to be eating enough food (82). This test was done before the year of 2000 as 
the only test for CD in Gaza Strip, due to the difficulty in supplying the 
materials for this test and the availability of fluorescence microscope in central 
laboratory, EMAs test replaced this test until now         
Blood levels of D-xylose are highest about 2 hours after the drinking the D-
xylose solution. Almost all of the D-xylose is eliminated from the body in the 
urine within 5 hours. If the intestines cannot absorb the D-xylose properly, the 
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amount of D-xylose in the blood and urine will be very low. The normal values 
for the test in blood are greater than 25 mg/dl (milligrams per deciliter) at one 
hours after ingestion. While in urine the levels are greater than 16% of 
ingested dose excreted within 5 hours of ingestion 
High values may be caused by a disease, such as Hogkin's disease or 
Radiation treatment.  
Low values on the otherhand may be caused by a disease that interferes with 
the intestine's ability to absorb nutrients (malabsorption syndrome), such as 
Crohn's disease, celiac disease, or Whipple's disease; Inflammation of the 
lining of the intestine or an infection with a parasite, such as giardiasis or 
hookworm (83). 
2.7.1.6 Lactose tolerance test 
Lactose is a disaccharide consisting of glucose and galactose. It is found in 
milk and other dairy products. The concentration of lactose in human milk is 
about 7% whereas in cow's milk it is about 5% (84). 
 Patients suffering from lactose intolerance are not able to cleave the 
alimentary disaccharide lactose. In contrast to milk protein allergy, lactose 
intolerance is not an atopic reaction of the immune system, but a loss of 
activity of the enzyme lactase. Lactose tolerant individuals can cleave lactose 
into its components glucose and galactose with the enzyme lactase, which is 
localized in the mucous membrane of the small intestine. This biochemical 
process leads to a measurable increase of blood glucose concentration. 
Lactose intolerant patients are suffering from reduced or missing lactase 
activity and therefore, lactose cannot be metabolized. Thus lactose is 
microbially fermented in the lower parts of the intestine. The non-fermented 
lactose leads to an increase of the osmotic activity in the intestine. Typical 





2.7.1.6.1 Reasons of lactose intolerance 
Genetic defects (primary lactose intolerance) or gastrointestinal diseases 
(secondary lactose intolerance) can cause lactose intolerance. The most 
severe form of primary lactose intolerance is alactasia (congenital lactase 
deficiency). Alactasia is a rare inherent enzyme defect (autosomal recessive), 
characterized by a total loss of lactase. Disorders like diarrhea, dehydration, 
and malnutrition can be seen in newborn infants and may lead to severe 
cerebral damages (86). 
2.7.1.6.2 Lactose intolerance diagnosis 
Two formal tests are commonly used in patients suspected of having lactose 
intolerance: 
v The Lactose Tolerance Test: 
The lactose tolerance test consists of administering an oral dose of 
approximately 1 to 1.5 g of lactose per kg of body weight and obtaining 
serial blood samples for measurement of blood glucose levels. The test is 
positive if intestinal symptoms occur and the blood glucose level increases 
less than 20 mg per dL above the fasting level. However, false-positive 
and false-negative test results occur in 20 percent of normal subjects 
because of the influence of variable gastric emptying and glucose 
metabolism (87). 
v The Hydrogen Breath Test: 
The measurement of breath hydrogen after ingestion of 25 to 50 g of 
lactose is more sensitive and specific than the lactose tolerance test. The 
breath hydrogen test has become widely available and is often used rather 
than the lactose tolerance test. The breath hydrogen test is based on the 
principle that carbohydrate in the colon is detectable in pulmonary 
excretion of hydrogen and other gases. A rise in breath hydrogen 
concentration greater than 20 ppm over baseline after lactose ingestion 
suggests hypolactasia (88). Very little hydrogen is normally detectable. 
However, undigested lactose in the colon is fermented by bacteria and 
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produces various gases, including hydrogen. The hydrogen is absorbed 
from the intestines, carried through the bloodstream to the lungs, and 
exhaled. In this test, the person drinks a lactose-loaded beverage and the 
breath is analyzed at regular intervals. Raised levels of hydrogen in the 
breath  indicate improper digestion of lactose. Certain foods, medications, 
and cigarettes can affect the accuracy of the test and should be avoided 



















































3.1 Study design 
  
The study is a descriptive one and conducted on  children suffering from 
chronic diarrhea, they examined for the following tests.: 
1-EMAs .(IgA). 
2- TTG. (IgA, IgG). 
3-TTG. (IgA). 
4- Total IgA 
5- ASMA. 
6- Jejunal biopsy-when available-for positive cases of any parameter to 
confirm the diagnosis was done. 
3.2 Inclusion criteria 
1- Children age above six month and  less than nine years. 
2- Have diarrhea more than three times daily. 
3- The diarrhea not caused by an infection. 
4- Patients setting in Gaza Strip 





   
Figure 3.1 A summary of the work plan. 
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3.3 Study population  
  
The study population comprised 123 symptomatic Palestinian children 
suffering from chronic diarrhea. The samples were received from Al-Rimal 
Clinic and Ard Al Ensan during the period from (April to June 2008)  . 
3.4 Sample collection 
Five ml peripheral blood were collected in vacuum plain tube under quality 
control assurance condition for each sample. Serum was separated in clean 
plastic tubes and stored at -70°C until performing the assay. 
3.5 Permissions and ethical consideration 
Permission was obtained from the Helsinki Committee for sample collection 
and oral consents from were also obtained from each patient where purpose 
of the study was explained and drawing extra blood if needed. 
3.6Materials 
3.6.1 Reagent kits 
The following assays were done: 
1-EMAs (IgA) qualitative test using indirect immunofluorescence technique (IFA), 
is purchased from Biosystem company from Espaniol. 
2- TTG (IgG, IgA) quantitative test using (ELISA) technique, is commercially 
available kit from Orgentic company from Germany. 
3-TTG (IgA) quantitative test using (ELISA) technique, it is commercially 
available kit from Orgentic company from Germany. 
4-ASMA: qualitative test using indirect immunofluorescence technique(IFA),it 
is commercially available kit from Biosystem company from Espaniol. 
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5-Total (IgA): quantitative test using radial immunodifusion (RID) technique, it 
is commercially available kit from Liofilchem company from Italy. 
6- Histopathological examination were executed by specialist when available 
in Al- Shifa hospital. 
3.6.2 Instruments and disposables 
ELISA reader (Statfax),Germany. 
Fluorescence Microscope, Zeius, Germany. 
Graduated flasks, different sizes. 
Graduated Cylinders (100, 500, 1000 )ml 
Syringes and needles 
Plasters 






Yellow and blue tips 
Timer 
Centrifuge 






3.6.3 Immunological investigations 
3.6.3.1 Antiendomysial Antibodies (EMAs  IgA) 
EMAs  was performed by applying Immunofluoresence assay (IFA) which is 
based on the indirect method of fluorescent antibody staining. The procedure 
is carried out in two steps. First,  the serum antibodies bind the specific 
antigenic substrate forming an antigen-antibody complex. In the second step, 
the formed complex reacted with added fluorescein-labeled anti human 
antibody. If serum antibodies are present the reaction yields a bright apple-
green fluorescence under the UV microscope (90). 
 Principle of the test 
 Serum anti-endomysium antibodies (EMAs) bind to the corresponding 
antigens present in a section of the lower one-third of the monkey esophagus. 
The resulting antigen-antibody complexes are detected by means of a 
fluorescein labeled anti-human immunoglobulin A, and visualized with the aid 
of a fluorescence microscope (91). 
v Composition 
A. Slides: Monkey esophagus sections (endomysium) in each well. 
B. Phosphate Buffered saline (PBS) (20x): Sodium phosphate 225 mmol/L, 
potassium phosphate 60 mmol/L, sodium chloride 2.3 mol/L, sodium azide 
0.95 g/L,pH 7.2. 
C. EMAs Positive Control: Human serum containing anti- endomysium 
antibodies), sodium azide 0.95 g/L. 
C. Negative Control: Human serum, sodium azide 0.95 g/L. 
D. IgA FITC/Evans: Goat anti-human IgA conjugated with fluorescein 
isothiocyanate (FITC), Evans blue 0.01 g/L, sodium azide 0.95 g/L. 
E. Mounting Medium: Glycerol 78%, sodium phosphate 6 mmol/L, 
potassium phosphate 1.6 mmol/L, sodium chloride 60 mmol/L, 
sodium azide 0.95 g/L. 
F. Blotting Paper. 
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v Reagent preparation 
PBS: The Reagent B was diluted 1/20 with distilled water. It is stable for 1 
week at 2-8ºC. All other reagents were provided ready to use. 
v Samples 
Serum collected by standard procedures. serum allowed to thaw, then diluted 
1/5 in PBS. For titration of positive samples, two-fold serial dilutions were 
made starting from 1/5 in PBS.  
 
v Procedure 
1. The reagents and samples were brought  to room temperature. 
2. one drop (50 μL) of the diluted sample or Control was delivered on each 
slide well (A), making sure that it is completely covered . 
3. The slide was incubated for 30 minutes at room temperature (15-30ºC) in  a 
moist chamber. 
4. Sample drops were drain off by gently tapping the inclinated slide. To avoid 
cross contamination of the sera. 
5. The slide was gently rinsed with PBS.  
6. The slide was thoroughly washed by immersing in a washing tray filled with 
PBS for 5 minutes.  
7. The slides Carefully dried off by using the blotting paper provided. the 
cells preparation were kept a moist along the procedure. 
8. One drop of the conjugate was delivered into each well. Then the slides 
were Incubated for 30 minutes at room temperature (15-30ºC) into a moist 
chamber. 
9. Washing (step 6) and drying (step 7). 
10. Several drops of mounting media reagent were delivered on the slide and 
covered with a cover slip avoiding the formation of air bubbles. 
 
 
v Reading the slides 
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The slides were examined using the fluorescence microscope (250-400x). For 
best results, the slides were read immediately and  specifically in fields in the 
inner part of the tissue section. As recommended by the manufacturer 
Fluorescent intensity in the tissue edge is not representative of the slide 
preparation. All sera showing network-like fluorescence labeling of the thin 
layer surrounding the smooth muscle fibers of monkey esophagus at the 
recommended dilution was considered positive (Figure 2.10). When none of 
the above specific stainings are observed, the result were considered 
negative for these autoantibodies. 
v Quality controls 
Positive Control and Negative Control provided with kit was tested together 
with the patients samples, in order to verify the assay performance. 
Positive Control should give the above described specific staining. 
Negative Control should not give any specific staining. 
  
3.6.3.2 Antismooth Muscle Antibodies (ASMA) 
 
The procedure of ASMA was the same steps as for EMAs  test except that the 
slides were coated by rat kidney and rat stomach.  
v Reading 
Sera showing staining of the muscularis mucosae (Figure 3.3), the muscle 
layers of the blood vessels and the interglandular fibers in the rat stomach at 
the recommended dilution were considered positive. When none of the above 






 (Figure 3.2) ASMA  staining reaction on rat stomach smooth muscle, 200X 
(93). 
 
3.6.3.3 Anti-Tissue-Transglutaminase (TTG IgG,IgA) 
v Name and intended use 
Anti-Tissue-Transglutaminase Screen an indirect solid phase enzyme linked 
immunosorbent assay (ELISA) for the simultaneous quantitative measurement 
of IgG and IgA class autoantibodies against tissue Transglutaminase (TTG) in 
human serum. The assay is intended for in vitro diagnostic use only as an aid 
in the diagnosis of celiac disease and dermatitis herpetiformis. 
v Principle of the test 
Human recombinant tissue Transglutaminase was bound to microwells. 
Antibodies against this antigen, if present in diluted serum, bind to the 
respective antigens. Washing of the micro wells removes unspecific serum 
and plasma components. Horseradish peroxidase (HRP) conjugated anti-
human IgG and IgA immunologically detect the patient antibodies forming a 
conjugate/antibody/antigen complex. Washing of the microwells removes 
unbound conjugate. An enzyme substrate in the presence of bound conjugate 
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hydrolyzes to form a blue color. The addition of an acid stops the reaction 
forming a yellow end-product. The intensity of this yellow color is measured 
photometrically at 450 nm. The amount of color is directly proportional to the 
concentration of IgG and IgA antibodies present in the original sample. 
v Contents of the kits 
• One divisible microplate consisting of 12 modules of 8 wells each, 
coated with human recombinant tissue Transglutaminase. Ready to 
use. 
• Six vials, 1.5 ml each combined Calibrators with IgG and IgA class 
Anti-TTG antibodies (A-F) in a serum/buffer matrix (PBS, BSA, NaN3 
<0,1% (w/w)) containing: IgG 0; 5; 10; 25; 75; and 200 U/ml and IgA: 0; 
5; 10; 25; 75; and 200 U/ml. Ready to use. 
• Two vials, 1,5 ml each Anti-TTG Controls in a serum/buffer matrix 
(PBS, bovine serum albumin (BSA), NaN3 <0,1% (w/w)) positive (1) 
and negative (2), for the respective concentrations. Ready to use. 
• one vial, 20 ml Sample buffer (Tris, NaN3 <0,1% (w/w)), yellow, 
concentrate (5x).  
• one vial, 15 ml Enzyme conjugate solution (PBS, PROCLIN 300 <0,5% 
(v/v)), (light red) containing polyclonal rabbit anti-human IgG, anti-
human IgA; labeled with horseradish peroxidase. Ready to use. 
• one vial, 15 ml TMB substrate solution. Ready to use. 
• one vial, 15 ml Stop solution (1 M hydrochloric acid). Ready to use. 
• one vial, 20 ml Wash solution (PBS, NaN3 <0,1% (w/w)), concentrate 
(50x). 
v Storage and stability 
1. The kit was Stored at 2-8 °C. 
2. Microplate wells were kept and sealed in a dry bag with desiccants. 
3. The reagents are stable until expiration of the kit. 
4. Test reagents were not exposed to heat, sun or strong light during storage 
and usage. 
5. sample buffer and washing buffer are stable for at least 30 days when 
stored at 2-8 °C. 
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v Sample preparation 
All patient samples were diluted 1:100 with sample buffer before assay. Then 
10 μl of sample was added to 990 μl of sample buffer in a polystyrene tube. 
Mixed well. Controls were ready to use and need not be diluted. 
v PREPARATION OF REAGENTS 
• Preparation of sample buffer 
The contents of each vial of the sample buffer concentrate (5x) were diluted 
with distilled or deionized water to a final volume of 100 ml prior to use. Stored 
refrigerated: (stable at 2-8 °C for at least 30 days after preparation or until the 
expiration date printed on the label). 
 
• Preparation of wash solution 
The contents of each vial of the buffered wash solution concentrate (50x) 
were diluted with distilled or deionized water to a final volume of 1000 ml prior 
to use. Store refrigerated: stable at 2-8 °C for at least 30 days after 
preparation or until the expiration date printed on the label. 
v Test procedure 
1. A sufficient number of microplate modules were prepared to accommodate 
controls and prediluted patient samples. 
2. One hundred μl of calibrators, controls and prediluted patient samples were 
delivered  duplicate into the wells. 
3. Incubated for 30 minutes at room temperature (20-28 °C). 
4. The contents of the microwells were discarded and then washed 3 times 
with 300 μl of wash solution. 
5. One hundred μl of enzyme conjugate were dispensed into each well. 
6. Incubated for 15 minutes at room temperature. 
7. The contents of the microwells were discarded and washed 3 times with 
300 μl of wash solution. 
8. One hundred μl of TMB substrate solution were dispensed into each well. 
9. Incubated for 15 minutes at room temperature. 
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10. One hundred μl of stop solution were added to each well of the modules 
and incubated for 5 minutes at room temperature. 
11. The optical density was read at 450 nm and the results were calculated. 
Bi-chromatic measurement with a reference at 600-690 nm is recommended 
by the manufacture. The developed color is stable for at least 30 minutes. 
optical densities were recorded during this time. 
v Interpretation of results 
In a reference value study with serum samples from healthy blood donors the 
following ranges have been established with the Anti-Tissue-Transglutaminae 
Screen tests: 
Anti-Tissue-Transglutaminase Screen 
normal: < 15 IU/mL 
positive: >15 IU/mL 
v Sensitivity 
The lower detection limit for Anti-Tissue-Transglutaminase Screen has been 
determined at 1.0 U/ml. 
v Specificity 
The solid phase is coated with human recombinant TTG. Therefore the Anti-
Tissue-Transglutaminase Screen test kit recognizes only IgG and IgA class 
autoantibodies specific for TTG (93,94,95,96). 
 
3.6.3.4 Anti-Tissue-Transglutaminase IgA 
The procedure of (TTG IgA) is the same as that used in (TTG IgG,IgA) test 
except that the interpretation of the result. 
v Interpretation of results 
In a normal range study with serum samples from healthy blood donors the 





Cut-Off: 10 [IU/ml] 
 
3.6.3.5 Total IgA 
v Assay principle 
Radial Immunodiffusion (RID) is a well established technique based on the 
binding of antigen and antibody to produce a visible precipitin ring in a gel. 
The IgA (antigen) in the serum which drained in the well of the plate diffused 
radially in the agarose gel reacting with specific antibodies incorporated in 
agarose gel and forming immune complexes visible ring. Diameter of the ring 
is directly proportion to the concentration of the IgA in the sample.   
 
v Kit Contents 
• One RID plates, 12 pre-cut wells per plate 
• Calibrators 
• Control 
• Sample diluent 
• Gel sectioning blades 
• Instruction leaflet and results table 
v Test procedure 
1. The plate was removed from the envelope and left for five minutes at 
room temperature . 
2. The wells were filled with 5µL of serum. 
3. After the sample diffused ,The plate was closed with the lid and 
incubated at room temperature for 48 hours. 
v Interpretation of the results 
After 48 hours the precipitation ring diameter was measured, The IgA 
concentration was read using the manufacturer tables. 
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v Quality control 
Quality control was carried out by performing a control of accuracy and 
precision inoculating a control serum on the plate in examination. The 
precision (95 %) and the accuracy +/- (85 %)(97).  
3.7 Statistical Analysis 
Data will be analyzed using appropriate SPSS version "15" for cleaning 
data and  to obtain the frequency of the data. 
3.8  Histopathological examination 
      Histopathological examination were executed by specialist when available. 
 






























4.1 Study population: 
The present study comprised 123 Palestinian children complaining from the 
following symptoms (chronic diarrhea, failure to thrive, malabsorption, short 
stature). Their ages were above 6 months and less than 96 months (mean 
age, 38.6 and median age,36). Among the samples, 51.6% were males and 
48.4% were females. The processing and testing of the samples were 
conducted in the immunology department in Al – Rimal clinic. 
........................................                                       
………………………………….……………………………………………………. 
4.2 Source of samples:  
Samples were obtained from two sources; Ard- El-Ensan (68%) and Al-Rimal 

















Figure  4.1 Source of samples 
 











.3 Preliminary study:4    
  
Initially we tested 2 samples for EMAs , the results were negative and 
uninterpreted due to the presence of ASMA antibodies in high 
concentrations due to the hook effect. 
The EMAs results were negative at serum dilution 1/5, when several 
dilution were made (1/10, 1/15, 1/20, 1/40 ), EMAs test was positive at 
dilutions of 1/15 and 1/20, the increasing serum dilution reduces the ASMA 
antibodies and decreases the effect of ASMA antibodies on EMAs 
antibodies so EMAs test will give positive result. 
In another experiment were the masking between EMAs and ASMA was 
clearly shown when I used EMAs positive sample and ASMA positive 
sample, the titer of ASMA positive sample was more than 1/160. Therefore  
serial dilutions were made for the serum of ASMA positive (1/5, 1/10, 1/20, 
1/40 ). I mixed the two samples, the test (EMAs) was performed by using 
the esophagus section. The 1/5 and 1/10 titers were negative EMAs test, 
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Figure 4.2: A summary of the work plan is illustrated in the following algorithm. 
Foote Notes: EMAs; Antiendomysial antibodies, ASMA; Anti smooth muscle 
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4.4 The results of EMAs 
All samples were tested for EMAs, only four samples showed positive results 



































4.5 The results of ASMA  
All EMAs negative samples were tested for ASMA. Only 35 samples were 
positive (28.45%). The rest (84) were negative. These results are shown in 

































4.6 The results of (TTG IgG,IgA)  
All positive samples for ASMA (35) were tested fore(TTG IgG,IgA) and the 
positive EMA subjects (4) were added to be tested for (TTG IgG,IgA). 15 
samples were positive, others were negative. These results are shown in 
figure 4.5 
Among the other 84 samples that were negative for both EMAs and ASMA, 
only 78 samples were tested. the results showed that all are negative for TTG 



































Figure 4.6 Comparison between; Results of TTG and EMAs among (117) 
samples  tested for both. 
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4.7 The results of Total IgA 
Total IgA test performed for the 15 samples which were positive for (TTG 
IgG,IgA). Five samples were deficient and others were within normal range. 































4.8 The results of (TTG IgA)  
The five deficient samples were tested for (TTG IgA). Three samples of them 















    
Figure 4.8 The results of TTG IgA  
 
4.9 The results of Histopathology 
 
Due to the difficulty of handling the histopathological examination( HPE) 
samples, only five patients were tested for HPE from the fifteen positive 
samples positive for (TTG IgG,IgA). The diagnosis of all samples was 
















 Overall of CD among examined samples4.10   
Based on the previous results the overall occurrence of CD among the study 
population (positive for EMAs, TTG or both) was 12.2%. These results are 
















                                      



























The present study is one of the important contributions to the child health and 
growth. 
A number of antibodies have been described as having an association with 
Celiac disease. These include AGA , TTG, EMAs antibodies. IgA anti-
endomysial antibodies have consistently been shown to have high sensitivity 
and specificity for celiac disease and they are measured by indirect immuno-
fluorescence assay. The main technical problem with this assay is that the 
presence of concomitant anti-smooth muscle antibody which makes the 
interpretation of the slides more difficult. The presence of a high titre anti-
smooth muscle antibody may make the test uninterpretable and an alternative 
serological test should be performed.  
EMAs results: In the current study, the EMAs positive samples were (4) 
giving the occurrence of CD among 123 symptomatic patients as of 3.25%.  
These results showed that the occurrence of EMAs among CD suspicious 
patients was lower than expected because many samples were positive for 
challenge and were EMAs negative test . 
When comparing these results to other studies, the current study results is 
lower than that reported by Rabab, In Saudi Arabia where the percentage was 
7.6%, among 145 patients with suspected CD depends on serological and 
HPE methods [98]. In another study reported by van and west in America the 
prevalence of CD among  suspected patients was .05%, and in other studies 
among different populations, the prevalence was higher than this study. The 
difference between this study and others could be due to several factors, 
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study population (selection of high risk group, symptoms, number of subjects 
enrolled in the study. High titer of ASMA antibodies which may mask the 
EMAs antibodies and gives false negative results of EMAs test. Genetic 
variation in the study population. 
ASMA results: according to the finding of this study the ASMA positive 
samples were 35 giving a percentage of 28.5%.  
 When comparing these results with other studies which were performed 
among normal population, it showed higher percentage than the current 
study. 
In a study reported by Anderso and his colleagues the prevalence of ASMA in 
normal population was (2-9%), they  tested 582 normal subjects of different 
ages (99). 
Many studies were performed to evaluate the prevalence of ASMA antibodies 
among normal population, the results were approximately in the range of the 
Anderson et al study. 
According to the researcher experience in the immunology department in Al- 
Rimal clinic there is increased occurrence of ASMA antibodies when testing 
the EMAs, ASMA and antinuclear antibodies. 
The high occurrence of ASMA in this study as compared to others may be 
due to several factors: The variation in study populations in different areas, In 
light of other studies ASMA antibodies may be highly occurring in normal 
subjects in Palestine. The normal value of ASMA in our population may be 
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different from other population, the samples dilution 1 to 20 and above is 
considered positive ASMA test, the normal dilutions of ASMA test may be 
more than 1 to 20. It is expected that there is a correlation between ASMA 
antibodies and CD, so the researchers must put into focus this matter. And 
Our target group comprised highly suspected children for CD, while others 
determined the prevalence among normal population. 
(TTG IgG, IgA) results: according to the current study, (TTG IgG, IgA) 
positive results were 11(9.2%) samples out of 119 in addition to 4 (3.25%) 
EMAs positive samples. 
 The occurrence of CD among symptomatic subjects (119) was 9.2%. The (4) 
positive EMAs samples were tested for  (TTG IgG, IgA), all of the  positive 
EMAs samples were positive for (TTG IgG, IgA). The total number of positive 
subjects was increased to (15), thus the occurrence of CD among 123 
symptomatic patients was increased to reach 12.2%.  
 When comparing our study results to other studies, our findings are more or 
less than other  studies. 
Our study showed lower percentage when compared with that of Liorente 
which revealed 15% positive results for (TTG IgG, IgA) (100).  
Most studies which are concerned with the prevalence of CD among 
symptomatic patients showed lower percentage than our study. 
The variation could be explained by the differences in the characteristic of our 
study population (genetics, different ethnics groups, etc.. ), the second cause 
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of our increased percentage may be due to consanguinity in which the DQ2, 
DQ8 genes pass to the siblings and increase the risk factors for CD. 
When the results of EMAs antibodies were compared to (TTG IgG, IgA) 
results in this study, the EMAs positive subjects were 4/123 (3.25%) samples 
but the (TTG IgG, IgA) positive samples were 11/123 (9.2). The variations 
between the two results could be explained by the high occurrence of ASMA 
antibodies which may mask the EMAs antibodies, so EMAs test may show 
false negative as reported by lasagna et al., (1999) [54].  
The EMAs response can be effectively unmasked by increasing the dilutions 
of ASMA positive serum, but the increasing of serum dilution is not always 
possible, when the EMAs antibodies are present at low concentration, the 
increasing of serum dilution will decrease the EMAs antibodies and may give 
false negative results.  
The preliminary study which the researcher made showed that the high titer of 
ASMA gives false negative EMAs test, the reason behind this matter may be 
due to masking of ASMA antibodies to EMAs antibodies as described above. 
It is supposed that the masking is not due to binding of ASMA antibodies to 
EMAs antibodies or to the epitops of the endomysial tissue because the 
fragments of antigen binding ( FAB) of the two antibodies are different. 
The following explanation may reveal the issue of the false negative EMAs 
results in the presence of ASMA antibodies in high titer: 
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1. Fluorescence masking: 
A strong positive results of ASMA means a strong Fluorescence green 
color in a broad area occupied by the muscle fibers when compared to the 
endomysial tissue which is a thin layer surrounding the  muscle fibers, so 
the high intensity of ASMA test prevents EMAs color to be interpreted. 
2. The high titer of ASMA antibodies may prevent the EMAs antibodies 
to reach the binding sites of endomysial tissue, when diluting the ASMA 
antibodies by titration, the EMAs antibodies will reach the endomysial 
tissue and gives positive results.  
In various studies researchers recommended using TTG test as the initial 
test in both normal population screening and for suspected individuals of 
having CD.  
The results of total IgA: All samples which were positive for (TTG IgG, 
IgA) were subsequently examined for total IgA. Ten samples showed 
normal results while the remaining five samples were deficient in total IgA 
(33.3%).  Our study showed an increase in the percentage of total IgA 
deficient subjects  when compared to other studies. In a study was 
reported by Kumar et al., (2002) the total IgA deficient subjects were  10 
to 15 times more in patients with celiac disease when compared to  
healthy subjects. IgA deficiency is one of the most frequent 
immunodeficiencies. The prevalence was estimated to be  one in 500 to 
one in 700 healthy persons, The incidence of IgA deficiency in patients 
with CD is somewhere between 2 and 3%, representing an increase of 10- 
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to 15-fold over the general population. The results of our study showed 
that the IgA deficient patients with CD yield false negative serological 
results when we are looking for the (IgA) of (EMAs ,TTG,AGA,). So it is 
recommended to test for IgG [52, 53]. 
The variation between our study and others may be due to the small 
number of subjects which were tested, so the 15 samples are not 
representative for the evaluation of total IgA deficiency, so we need more 
investigations to ensure the total IgA deficiency in CD patients. Moreover 
no studies were performed to evaluate the total IgA deficiency in Gaza 
Strip.  
The results of (TTG IgA ): The five samples which were deficient for total 
IgA were   tested for (TTG IgA ), Three samples were negative and two 
samples  were positive.  
The results of the current study have proven that in case of total IgA 
deficiency in patients with CD when they were tested for TTG IgA yield 
false negative serological results, these finding are in agreement with 
other studies as discussed above [52,53]. Although the results of these 
three samples were positive when were tested for (TTG IgG, IgA) and 
were negative when were tested for (TTG IgA), these results showed that 
the (TTG IgG) were positive. Our findings are compatible with that of other 
studies as discussed above. In the other two positive subjects for (TTG 
IgA) which were total IgA deficient, the reason behind these results is due 
to the accuracy of the total IgA test = +/- 15%, if I added this value to the 
test value, the 2 deficient subjects will be normal ones, this explanation 
 61
reveal the ambiguity from the 2 positive subjects for (TTG IgA) and total 
IgA deficiency. 
The results of Histopathology: Due to difficulty in handling the HPE, only 
five samples were tested for HPE, Four of the samples were positive for  
(TTG IgG, IgA) and EMAs negative but the results of ASMA were positive, 
1/5 subject was (TTG IgG, IgA) and EMAs positive while negative for 
ASMA test. The diagnosis of all samples was consistent with CD. 
 Results are compatible with those of other studies, such as that 
reported by Olsson and his results who indicated that the positive (TTG 
IgG, IgA) is consistent with the results of HPE and is correlated with the 
grade of mucosal villous atrophy [75]. 
The five HPE subjects are neither  enough nor representative to evaluate 
the relation between the TTG test and HPE (mucosal villous atrophy), so 
this need more studies to prove this matter. 



























6.1 Conclusions  
The results of the study can be summarized as follow: 
v Examination of the 123 samples by using EMAs showed an occurrence of 
CD 3.25%, but when were examined by using (TTG IgG, IgA) the 
occurrence was12.2%. 
v Our results showed that the occurrence of ASMA was 28.5% which may 
mask the EMAs antibodies and showd false negative results. 
v Positive samples for ASMA (n=35) were tested for (TTG IgG, IgA), 11 
subjects of these were positive for (TTG IgG, IgA), these results proves 
the existence of false negative results of EMAs in the presence of ASMA. 
v The four positive samples for EMAs showed positive results when they 
were tested for(TTG IgG, IgA), these results mean that the two tests have 
the same sensitivity. 
v Our finding showed that the total IgA deficiency represent (33.3%) from all 
(TTG IgG, IgA) positive samples, these results were negative when tested 
for (TTG IgA), so the class IgG of EMAs and TTG must be done for CD 











v  Following our results obtained in this study, I propose the following 





Suspicion of CD patient with 





























Figure 6.1 protocol for laboratory diagnosis of CD. 
HPE; HPEstopathological examination, CD; celiac disease, TTG IgA; tissuetransglutaminase  IgA, 




v  The role of ASMA in (masking) the EMAs could be investigated in future   
research. 
v  The prevalence of ASMA should be studied in general population to 
define dilution cut off for the test. 
v  Introducing the genetic analysis of CD to identify persons with increase 
risk of having the disease. 
v  Adopt HPE as a golden standard test for clinical assessment of the 
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The study specimens results 
NO. TTG   
IgG, IgA 
EMAs IgA TTG IgA HPE ASMA 
1 Negative Negative . . . Negative 
2 Negative Negative . . . Negative 
3 Negative Negative . . . Negative 
4 Negative Negative . . . Positive 
5 Negative Negative . . . Negative 
6 Negative Negative . . . Negative 
7 Negative Negative . . . Negative 
8 Negative Negative . . . Negative 
9 Negative Negative . . . Negative 
10 Positive Negative Deficient Negative . Positive 
11 Negative Negative . . . Negative 
12 Negative Negative . . . Negative 
13 Positive Negative Deficient Positive . Positive 
14 Negative Negative . . . Negative 
15 Negative Negative . . . Negative 
16 Negative Negative . . . Negative 
17 Negative Negative . . . Negative 
18 Negative Negative . . . Negative 
19 Negative Negative . . . Negative 
20 Negative Negative . . . Negative 
21 Negative Negative . . . Negative 
22 Negative Negative . . . Negative 
23 Negative Negative . . . Positive 
24 Negative Negative . . . Negative 
25 Negative Negative . . . Negative 
26 Negative Negative . . . Negative 
27 Positive Negative Normal . . Positive 
28 Negative Negative . . . Negative 
29 Negative Negative . . . Negative 
30 Negative Negative . . . Negative 
31 Negative Negative . . . Negative 
32 Negative Negative . . . Negative 
33 Negative Negative . . . Negative 
34 Negative Negative . . . Negative 
35 Negative Negative . . . Negative 
36 Negative Negative . . . Negative 
37 Negative Negative . . . Negative 
38 Negative Negative . . . Negative 
39 Negative Negative . . . Negative 
40 Negative Negative . . . Negative 
41 Negative Negative . . . Negative 
42 Negative Negative . . . Negative 
43 Negative Negative . . . Negative 
44 Negative Negative . . . Positive 
45 Negative Negative . . . Negative 
46 Negative Negative . . . Negative 
47 Negative Negative . . . Negative 
48 Negative Negative . . . Negative 
49 Negative Negative . . . Negative 
50 Negative Negative . . . Negative 
51 Negative Negative . . . Negative 
 76
NO. TTG   IgG, IgA EMAs IgA TTG IgA HPE ASMA 
52 Negative Negative . . . Negative 
53 Negative Negative . . . Negative 
54 Negative Negative . . . Negative 
55 Negative Negative . . . Negative 
56 Negative Negative . . . Negative 
57 Negative Negative . . . Positive 
58 Negative Negative . . . Negative 
59 Negative Negative . . . Negative 
60 Negative Negative . . . Negative 
61 Negative Negative . . . Positive 
62 Negative Negative . . . Negative 
63 Negative Negative . . . Negative 
64 Negative Negative . . . Negative 
65 Negative Negative . . . Negative 
66 Negative Negative . . . Negative 
67 Negative Negative . . . Negative 
68 Negative Negative . . . Negative 
69 Negative Negative . . . Positive 
70 Negative Negative . . . Positive 
71 Negative Negative . . . Negative 
72 Negative Negative . . . Positive 
73 Negative Negative . . . Positive 
74 Negative Negative . . . Negative 
75 Negative Negative . . . Negative 
76 Negative Negative . . . Negative 
77 Negative Negative . . . Positive 
78 Negative Negative . . . Positive 
79 Positive Positive Normal . Positive Negative 
80 Negative Negative . . . Positive 
81 Negative Negative . . . Positive 
82 Negative Negative . . . Positive 
83 Negative Negative . . . Positive 
84 Negative Negative . . . Negative 
85 Negative Negative . . . Negative 
86 Negative Negative . . . Negative 
87 Positive Negative Normal . . Positive 
88 Positive Negative Deficient Negative . Positive 
89 Negative Negative . . . Negative 
90 Negative Negative . . . Negative 
91 Negative Negative . . . Positive 
92 Negative Negative . . . Negative 
93 Negative Negative . . . Positive 
94 Negative Negative . . . Negative 
95 Positive Positive Normal . . Negative 
96 Negative Negative . . . Negative 
97 Negative Negative . . . Positive 
98 Negative Negative . . . Positive 
99 Positive Negative Deficient Positive . Positive 
100 Positive Positive Normal . . Negative 
101 Negative Negative . . . Positive 
102 Negative Negative . . . Negative 
103 Negative Negative . . . Negative 
104 Negative Negative . . . Negative 
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105 Negative Negative . . . Negative 
106 Negative Negative . . . Negative 
107 Negative Negative . . . Negative 
108 . Negative . . . Negative 
109 . Negative . . . Negative 
110 Negative Negative . . . Positive 
111 . Negative . . . Negative 
112 Negative Negative . . . Positive 
113 . Negative . . . Negative 
114 . Negative . . . Negative 
115 Positive Negative Normal . . Positive 
116 Negative Negative . . . Positive 
117 . Negative . . . Negative 
118 Positive Negative Normal . Positive Positive 
119 Negative Negative . . . Positive 
120 Positive Negative Normal . Positive Positive 
121 Positive Negative Deficient Negative Positive Positive 
122 Positive Negative Normal . Positive Positive 
123 Positive Positive Normal . . Negative 
 
 
